Docosahexaenoic acid reduces amyloid-β induced toxicity in cells of the neurovascular unit

Journal of Alzheimer's Disease

Volumn 36, Issue 3, 2013, Pages 487-501

  Veszelka, Szilvia ^a   Tóth, Andrea E ^a   Walter, Fruzsina R ^a   Datki, Zsolt ^b   Mózes, Emese ^b   Fülöp, Lívia ^b   Bozsó, Zsolt ^b   Hellinger, Éva ^c   Vastag, Monika ^c   Orsolits, Barbara ^a   Környei, Zsuzsanna ^a   Penke, Botond ^b   Deli, Mária A ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c GEDEON RICHTER LTD   (Hungary)

Author keywords

Alzheimer's disease; amyloid ; blood brain barrier; brain endothelial cells; docosahexaenoic acid; glia; neuron; neurovascular unit; P glycoprotein; pericyte

Indexed keywords

AMYLOID BETA PROTEIN; DOCOSAHEXAENOIC ACID; MULTIDRUG RESISTANCE PROTEIN; REACTIVE OXYGEN METABOLITE; RHODAMINE 123;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN SLICE; CELL VACUOLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; GLIA CELL; HIPPOCAMPUS; NEUROPROTECTION; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENILE PLAQUE; SMOOTH MUSCLE FIBER; TOXICITY TESTING;

EID: 84881397400     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-120163     Document Type: Article

References (78)

1. Neuwelt EA, Bauer B, Fahlke C, Fricker G, Iadecola C, Janigro D, Leybaert L, Molnár Z, O'Donnell ME, Povlishock JT, Saunders NR, Sharp F, Stanimirovic D,Watts RJ, Drewes LR (2011) Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci 12, 169-182
2. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28, 202-208
3. Deli MA (2005) The role of blood-brain barrier in neurodegenerative diseases. In Molecular Bases of Neurodegeneration, Di Liegro I, Savettieri G, eds. Research Signpost, Kerala, India, pp. 137-161
4. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201
5. Jaeger LB, Dohgu S, Hwang MC, Farr SA, Murphy MP, Fleegal-Demotta MA, Lynch JA, Robinson SM, NiehoffML, Johnson SN, Kumar VB, Banks WA (2009) Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance and increases brain levels of amyloid- βprotein and impairs cognition. J Alzheimers Dis 17, 553-570
6. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37, 13-25
7. Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B (2000) Clearance of amyloid β-peptide from brain: Transport or metabolism. Nat Med 6, 718-719
8. BanksWA, Niehoff ML, Drago D, Zatta P (2006) Aluminum complexing enhances amyloid beta protein penetration of blood-brain barrier. Brain Res 1116, 215-221
9. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, BretelerMM(1997) Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42, 776-782
10. Morris MC, EvansDA, Bienias JL, Tangney CC, BennettDA, Wilson RS, Aggarwal N, Schneider J (2003) Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60, 940-946
11. Lopez LB, Kritz-Silverstein D, Barrett Connor E (2011) High dietary and plasma levels of the omega-3 fatty acid docosahexaenoic acid are associated with decreased dementia risk: The Rancho Bernardo study. J Nutr Health Aging 15, 25-31
12. Morley JE, Banks WA (2010) Lipids and cognition. J Alzheimers Dis 20, 737-747
13. Hógyes E, Nyakas C, Kiliaan A, Farkas T, Penke B, Luiten PG (2003) Neuroprotective effect of developmental docosahexaenoic acid supplement against excitotoxic brain damage in infant rats. Neuroscience 119, 999-1012
14. Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D, Gibney MJ (2003) Low serum cholesteryl esterdocosahexaenoic acid levels in Alzheimer's disease: A casecontrol study. Br J Nutr 89, 483-489
15. Söderberg M, Edlund C, Kristensson K, Dallner G (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26, 421-425
16. LimGP, Calon F, MoriharaT,Yang F,Teter B, Ubeda O, Salem NJr, Frautschy SA, Cole GM (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25, 3032-3040
17. Oksman M, Iivonen H, Hógyes E, Amtul Z, Penke B, Leenders I, Broersen L, Lütjohann D, Hartmann T, TanilaH(2006) Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-Amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 23, 563-572
18. Arsenault D, Julien C, Tremblay C, Calon F (2011) DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3 x TG-AD mice. PLoS ONE 6, e17397
19. Freund-LeviY, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Fax́en-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study:Arandomized double-blind trial. Arch Neurol 63, 1402-1408
20. Kotani S, Sakaguchi E,Warashina S, Matsukawa N, Ishikura Y, Kiso Y, Sakakibara M, Yoshimoto T, Guo J, Yamashima T (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56, 159-164
21. Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY (2008) The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 32, 1538-1544
22. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CRJr, Weiner M, Shinto L, Aisen PS (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA 304, 1903-1911
23. Grimm MO, Kuchenbecker J, Grösgen S, Burg VK, Hundsdörfer B, Rothhaar TL, Friess P, deWildeMC,Broersen LM, Penke B, Ṕeter M, V́igh L, Grimm HS, Hartmann T (2011) Docosahexaenoic acid reduces amyloid β: production via multiple pleiotropic mechanisms. J Biol Chem 286, 14028-14039
24. Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, Bazan NG (2011) Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase-And PPARβ-mediated mechanisms in Alzheimer's disease models. PLoS ONE 6, e15816
25. HashimotoM,KatakuraM,Hossain S, Rahman A, ShimadaT, Shido O (2011) Docosahexaenoic acid withstands the A-(25-35)-induced neurotoxicity in SH-SY5Y cells. J Nutr Biochem 22, 22-29
26. Nakagawa S, Deli MA, Kawaguchi H, Shimizudani T, Shimono T, Kittel Á, Tanaka M, Niwa M (2009) A new blood-brain barrier model using brain endothelial cells, pericytes and astrocytes. Neurochem Int 54, 253-263
27. T́oth A, Veszelka S, Nakagawa S, Niwa M, Deli MA (2011) Patented in vitro blood-brain barrier models in CNS drug discovery. Recent Pat CNS Drug Discov 6, 107-118
28. Bozso Z, Penke B, Simon D, Laczḱo I, Juhász G, Szegedi V, Kasza A, Sóos K, Het́enyi A, Ẃeber E, Tóháti H, Csete M, Zarándi M, Fülöp L (2010) Controlled in situ preparation of Aβ (1-42) oligomers from the isopeptide "iso-A-(1-42) ", physicochemical and biological characterization. Peptides 31, 248-256
29. Környei Z, T́oth B, Tretter L, Madarász E (1998) Effects of retinoic acid on rat forebrain cells derived from embryonic and perinatal rats. Neurochem Int 33, 541-549
30. Deli MA, Jóo F, Krizbai I, Lengyel I, Nunzi GM, Wolff JR (1993) Calcium/calmodulin stimulated protein kinase II is present in primary cultures of cerebral endothelial cells. J Neurochem 60, 1960-1963
31. Kis B, Deli MA, Kobayashi H, Á brahám CS, Yanagita T, Kaiya H, Isse T, Nishi R, Gotoh S, Kangawa K, Wada A, Greenwood J, Niwa M, Yamashita H, Ueta Y (2001) Adrenomedullin regulates blood-brain barrier functions in vitro. Neuroreport 12, 4139-4142
32. Veszelka S, Pászt́oi M, Farkas AE, Krizbai I, Dung NTK, Niwa M, Á brahám CS, Deli MA (2007) Pentosan polysulfate protects brain endothelial cells against bacterial lipopolysaccharide-induced damages. Neurochem Int 50, 219-228
33. Perrière N, Demeuse P, Garcia E, Regina A, Debray M, Andreux JP, Couvreur P, Scherrmann JM, Temsamani J, Couraud P-O, Deli MA, Roux F (2005) Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J Neurochem 93, 279-289
34. Nakagawa S, Deli MA, Nakao S, Honda M, Hayashi K, Nakaoke R, Kataoka Y, Niwa M (2007) Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell Mol Neurobiol 27, 687-694
35. Ceruti S, Colombo L, Magni G, Viganò F, Boccazzi M, Deli MA, Sperlágh B, Abbracchio MP, Kittel á (2011) Oxygenglucose deprivation increases the enzymatic activity and the microvesicle-mediated release of ectonucleotidases in the cells composing the blood-brain barrier. Neurochem Int 59, 259-271
36. Dore-Duffy P, Katychev A, Wang X, Van Buren E (2006) CNS microvascular pericytes exhibit multipotential stem cell activity. J Cereb Blood Flow Metab 26, 613-624
37. Vandenhaute E, Dehouck L, Boucau MC, Sevin E, Uzbekov R, TardivelM, Gosselet F, Fenart L, Cecchelli R, DehouckMP (2011) Modelling the neurovascular unit and the blood-brain barrier with the unique function of pericytes. Curr Neurovasc Res 8, 258-269
38. Datki Z, Hunya A, PenkeB(2007)Anovel and simple fluorescence method for the measurement of presynaptic vesicular zinc release in acute hippocampal slices with a fluorescence plate reader. Brain Res Bull 74, 183-187
39. Datki Z, Juhász A, Gálfi M, Sóos K, Papp R, Zádori D, Penke B (2003) Method for measuring neurotoxicity of aggregating polypeptides with the MTT assay on differentiated neuroblastoma cells. Brain Res Bull 62, 223-229
40. Deli MA, Á brahám CS, Kataoka Y, Niwa M (2005) Permeability studies on in vitro blood-brain barrier models: Physiology, pathology, and pharmacology. Cell Mol Neurobiol 25, 59-127
41. Fontaine M, Elmquist WF, Miller DW (1996) Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessels endothelial cell monolayers. Life Sci 59, 1521-1531
42. Perrière N, Yousif S, Cazaubon S, Chaverot N, Bourasset F, Cisternino S, Declèves X, Hori S, Terasaki T, Deli M, Scherrmann JM, Temsamani J, Roux F, Couraud PO (2007) A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters. Brain Res 1150, 1-13
43. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193, 265-275
44. Deli MA, Veszelka S, Csiszár B, Tóth A, Kittel Á, Csete M, Sipos Á, Szalai A, Fülöp L, Penke B, Á brahám CS, Niwa M (2010) Protection of the blood-brain barrier by pentosan against amyloid-β-induced toxicity. J Alzheimers Dis 22, 777-794
45. Abramov AY, Canevari L, Duchen MR (2004) Calcium signals induced by amyloid beta peptide and their consequences in neurons and astrocytes in culture. Biochim Biophys Acta 1742, 81-87
46. Verdier Y, Zarándi M, Penke B (2004) Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: Binding sites and implications for Alzheimer's disease. J Pept Sci 10, 229-248
47. András IE, Rha G, Huang W, Eum S, Couraud P-O, Romero IA, Hennig B, ToborekM(2008) Simvastatin protects against amyloid β and HIV-1 Tat-induced promoter activities of inflammatory genes in brain endothelial cells. Mol Pharmacol 73, 1424-1433
48. Verbeek MM, de Waal RM, Schipper JJ, Van Nostrand WE (1997) Rapid degeneration of cultured human brain pericytes by amyloid beta protein. J Neurochem 68, 1135-1141
49. WilhelmusMM,Otte-Holler I, van Triel JJ,Veerhuis R, Maat-Schieman ML, Bu G, de Waal RM, Verbeek MM (2007) Lipoprotein receptor-related protein-1 mediates amyloid-β-mediated cell death of cerebrovascular cells. Am J Pathol 171, 1989-1999
50. Jeynes B, Provias J (2008) Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Curr Alzheimer Res 5, 432-437
51. Preston JE, Hipkiss AR, Himsworth DT, Romero IA, Abbott NJ (1998) Toxic effects of β-Amyloid(25-35) on immortalized rat brain endothelial cell: Protection by carnosine, homocarnosine and β-Alanine. Neurosci Lett 242, 105-108
52. Carrano A, Hoozemans JJ, van der Vies SM, Rozemuller AJ, van Horssen J, de Vries HE (2011) Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 15, 1167-1178
53. Tixier-Vidal A, Picart R, Loudes C, Bauman AF (1986) Effects of polyunsaturated fatty acids and hormones on synaptogenesis in serum-free medium cultures of mouse fetal hypothalamic cells. Neuroscience 17, 115-132
54. Greiner RS, Moriguchi T, Hutton A, Slotnick BM, Salem N Jr. (1999) Rats with low levels of brain docosahexaenoic acid show impaired performance in olfactory-based and spatial learning tasks. Lipids 34, S239-S243
55. Gamoh S, Hashimoto M, Sugioka K, Hossain MS, Hata N, MisawaY(1999) Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience 93, 237-241
56. Karr JE, Alexander JE, Winningham RG (2011) Omega-3 polyunsaturated fatty acids and cognition throughout the lifespan. Nutr Neurosci 14, 216-225
57. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, LazdunskiM(2000) Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 19, 1784-1793
58. Hashimoto M, TanabeY, FujiiY, Kikuta T, Shibata H, ShidoO (2005) Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid β-infused rats. J Nutr 135, 549-555
59. Calon F, LimGP,Yang F, MoriharaT,Teter B, UbedaO(2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43, 633-645
60. Lagarde M, Bernoud N, Brossard N, Lemaitre-Delaunay D, Thiès F, Croset M, Lecerf J (2001) Lysophosphatidylcholine as a preferred carrier form of docosahexaenoic acid to the brain. J Mol Neurosci 16, 201-204
61. Ouellet M, Emond V, Chen CT, Julien C, Bourasset F, Oddo S, LaFerla F, Bazinet RP, Calon F (2009) Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: An in situ cerebral perfusion study. Neurochem Int 55, 476-482
62. B́enistant C, Dehouck MP, Fruchart JC, Cecchelli R, Lagarde M(1995) Fatty acid composition of brain capillary endothelial cells: Effect of the coculture with astrocytes. J Lipid Res 36, 2311-2319
63. Lecomte M, Paget C, Ruggiero D, Wiernsperger N, Lagarde M (1996) Docosahexaenoic acid is a major n-3 polyunsaturated fatty acid in bovine retinal microvessels. J Neurochem 66, 2160-2167
64. Roig-Ṕerez S, Cortadellas N, Moret́o M, Ferrer R (2010) Intracellular mechanisms involved in docosahexaenoic acidinduced increases in tight junction permeability in Caco-2 cell monolayers. J Nutr 140, 1557-1563
65. Paget C, Lecomte M, Ruggiero D, Wiernsperger N, Lagarde M (1998) Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products. Free Radic Biol Med 25, 121-129
66. Quimby S, Fern R (2011) Novel morphological features of developing white matter pericytes and rapid scavenging of reactive oxygen species in the neighbouring endothelia. J Anat 219, 65-77
67. András IE, Eum SY, Toborek M (2012) Lipid rafts and functional caveolae regulate HIV-induced amyloid beta accumulation in brain endothelial cells. Biochem Biophys Res Commun 421, 177-183
68. Yang X, ShengW, SunGY, Lee JC (2011) Effects of fatty acid unsaturation numbers on membrane fluidity and β-secretasedependent amyloid precursor protein processing. Neurochem Int 58, 321-329
69. Pardridge WM (2002) Drug and gene targeting to brain with molecular Trojan horses. Nat Rev Drug Disc 1, 131-139
70. Tai LM, Loughlin AJ, Male DK, Romero IA (2009) Pglycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta. J Cereb Blood Flow Metab 29, 1079-1083
71. Candela P, Gosselet F, Saint-Pol J, Sevin E, Boucau MC, Boulanger E, Cecchelli R, Fenart L (2010) Apicalto-basolateral transport of amyloid-β peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by Pglycoprotein. J Alzheimers Dis 22, 849-859
72. Vogelgesang S, Jedlitschky G, Brenn A, Walker LC (2011) The role of the ATP-binding cassette transporter P-glycoprotein in the transport of β-Amyloid across the loodbrain barrier. Curr Pharm Des 17, 2778-2786
73. Kania KD, Wijesuriya HC, Hladky SB, Barrand MA (2011) Beta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells. Brain Res 1418, 1-11
74. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, Cascorbi I, Walker LC, Kroemer HK, Warzok RW, Vogelgesang S (2007) MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 17, 347-353
75. van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC,Windhorst AD, Comans EF, Hoetjes NJ, Tolboom N, Langer O, Müller M, Scheltens P, Lammertsma AA, van Berckel BN (2012) Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 135, 181-189
76. Floyd RA, Hensley K (2002) Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 23, 795-807
77. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 279, 13256-13264
78. Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla CJ, Reis M, Felici A, Wolburg H, Fruttiger M, Taketo MM, von Melchner H, Plate KH, Gerhardt H, Dejana E (2008) Wnt/beta-catenin signaling controls development of the blood-brain barrier. J Cell Biol 183, 409-417